Intrinsiqq

DexCom, Inc. (DXCM) Quality Score

DXCM
Quality91

Business quality and growth are strong, valuation is the relative weak spot (avg 60/100).

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
40/100
34.1x

Above 30x, priced for sustained outperformance

Cash Flow Multiple
80/100
23.1x

20–25x, moderate cash flow premium

Revenue Growth
100/100
14.3%

Above 10% CAGR, strong compounder

Cash Flow Growth
100/100
46.5%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
100/100
-8.7%

Shrinking >2%, active buybacks

Margin Trend
100/100
+9.5pp

Expanded 3+pp, strong improvement

Capital Structure
100/100
-$411M

Net cash position, no leverage concern

2022
$2.45B
$1.38B
2023
$2.73B
$2.60B
2024
$2.34B
$1.39B
2025
$2.00B
$1.40B
TTM
$1.81B
$1.40B
Return on Capital
100/100
20.7%

Above 20%, exceptional capital efficiency

Customize WeightsPremiumUpgrade

DexCom (DXCM) quality: score, margins and returns

DexCom (DXCM) scores 91/100 on Intrinsiqq's quality score (a high-quality business), a weighted blend of 8 metrics each scored 0 to 100, on 22.9% operating margins and 20.7% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is DexCom (DXCM) a high-quality business?+

DexCom scores 91 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a high-quality business on these measures. Recent figures include a 22.9% operating margin and a 20.7% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does DexCom's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from DXCM's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where DexCom scores well and where it falls behind.

What is DexCom's return on invested capital (ROIC)?+

DexCom earns about 20.7% on its invested capital, which is exceptional. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to DXCM's margins and growth on this scorecard to judge durability.

How profitable is DexCom?+

DexCom runs an operating margin of about 22.9% and a net margin of about 20.1%. Revenue has grown at roughly 19.3% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 23 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 3 Aug 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Related stocks: Surgical & Medical Instruments & Apparatus

Spot a number that looks wrong?

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.